eMedicine Specialties > Infectious Diseases > Skin and Soft-Tissue Infections

Pediculosis: Treatment & Medication

Author: Lyn Guenther, MD, FRCP(C), Professor, Department of Medicine, Division of Dermatology, University of Western Ontario; Chief of Dermatology, London Health Sciences Center; Medical Director, The Guenther Dermatology Research Centre, Canada
Coauthor(s): Sheilagh Maguiness, BSc, MD, Department of Dermatology, University of Alberta; Thomas W Austin, MD, Professor Emeritus, Department of Medicine, Division of Infectious and Sexually Transmitted Diseases, University of Western Ontario, Canada
Contributor Information and Disclosures

Updated: May 5, 2009

Treatment

Medical Care

P humanus corporis

  • Treatment of P humanus corporis infestation with any pediculicide is usually unnecessary because the louse lives on the clothing.
  • Treatment of clothing and bed linens includes washing them in hot water and drying them with high heat. Dry cleaning is also effective for killing lice and their nits on clothing.
  • Education about hygiene and accessibility to laundering facilities are important in preventing the spread of body lice and reinfestation.8
  • In cases of heavy pediculosis, treatment of the body with a pediculicide shampoo or lotion may be beneficial, especially if the patient also has confirmed or suspected concomitant head or pubic louse infestation. Oral ivermectin 12 mg given as 3 doses 7 days apart has also been shown to be efficacious in a cohort of homeless men.9

P humanus capitis and P pubis

  • Pediculicides: These include permethrin, lindane, malathion, or mercuric oxide ointment.
    • The pyrethroids are neurotoxic to lice; however, they are not very effective against developing nits, although they do have a residual effect. Lotions appear to be more efficacious than shampoos because of their increased contact time with the skin and hair of affected areas. Permethrin is available as a 1% solution (Nix) and as a 5% solution (Elimite), and a formulation of pyrethrin and piperonyl butoxide (Rid) is available. A-200 shampoo also contains benzyl alcohol. Permethrins are usually the first line of treatment, although resistance to permethrin is an increasingly important problem.
    • Lindane (hexachlorocyclohexane, a chlorinated hydrocarbon) is in the same pharmacologic class as dichlorodiphenyl trichloroethane (DDT). The use of lindane is controversial because of its known CNS toxicity.10 The compound is extremely lipid-soluble and is therefore highly permeable to the CNS. Acute lindane poisoning has been reported after ingestion of amounts as small as 5 mL or 50 mg. Kwell (lindane shampoo) has been removed from the Canadian market because of the availability of safer alternatives.
    • Malathion (Ovide) is an irreversible acetylcholinesterase inhibitor that is specific for insects. The US Food and Drug Administration (FDA) recently approved malathion for use against head lice in the United States. Malathion is available as a 0.5% and a 1% solution.
    • A study in children showed that treatment with Chick-Chack, a natural remedy that contains coconut oil, anise oil, and ylang ylang oil, had greater than 90% efficacy.11
    • Mercuric oxide ointment is useful in the treatment of eyelash infestation with P pubis.
    • Resistance to over-the-counter pediculicides (eg, permethrin, pyrethrin) is common, leading some parents to use toxic prescription medications containing lindane and malathion.
      • Benzyl alcohol lotion 5% was recently approved by the FDA for P capitis infestation. Although benzyl alcohol lotion needs to be applied twice, it might be an easier and safer alternative to lindane and malathion. With all treatments used to eliminate live lice, careful combing and removal of all nits from the hair, as well as cleaning of other articles (ie, hair accessories, towels, bedding, clothing), are essential steps to prevent reinfestation.
      • The safety and effectiveness of benzyl alcohol lotion 5% was demonstrated in 2 multicenter, randomized, double-blind studies of 628 patients aged 6 months and older with active head lice infestation. The participants received two 10-minute treatments of either benzyl alcohol lotion or topical placebo, 1 week apart. When observed 2 weeks following the final treatment, more than 75% of those treated with benzyl alcohol lotion were lice-free, whereas 4.8%-26.2% who received the placebo vehicle were lice-free.12
  • Asphyxiants: Petrolatum (twice daily for 7-10 days) is often used, with good results, for eyelash infestation. The petrolatum covers the lice and their nits, preventing respiration. The dead lice are removed mechanically, usually with tweezers.
  • Specific oral antibiotics: Oral antihelminthics, including ivermectin, levamisole, and albendazole,13 have been found to be effective against head louse infestation. Administration should be repeated in 7-10 days to kill lice emerging from nits that may have survived the first treatment. Co-trimoxazole (ie, trimethoprim and sulfamethoxazole) was initially reported to be efficacious; however, controlled studies have shown only minimal eradication.
  • Mechanical removal and shaving
    • Solvents are available to help dissolve the cement away from the nit and to aid in mechanical removal of nits with fine-tooth combs (eg, LiceMeister). Formic acid and plain white vinegar have been shown to be effective solvents.
    • Most studies have shown that mechanical removal alone (ie, wet-combing every 2-3 d for a minimum of 2 wk) is not as effective as when this technique is combined with a pediculicide.14
    • Shaving is effective but is usually not necessary or socially acceptable. However, in resistant disease, it may be a consideration.

Medication

The goals of pharmacotherapy are to eradicate the infestation, to prevent complications, and to reduce morbidity.

Pediculicides

In cases of heavy pediculosis, treatment of the body with a pediculicide shampoo or lotion may be beneficial, especially if the patient also has confirmed or suspected concomitant head or pubic louse infestation.


Permethrin (Nix, Acticin, Elimite)

Usually the first line of treatment in head, pubic, and severe body louse infestation. Available as a lotion and shampoo.

Adult

Wash hair with nonmedicated shampoo and towel dry; apply 1% lotion to affected areas; leave on hair for 10 min before rinsing; second application may be used in 7 d prn

Pediatric

Apply as in adults

Pregnancy

B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals

Precautions

Adverse effects include pruritus, burning, stinging, numbness, erythema, and edema of the scalp; discontinue use upon irritation or hypersensitivity


Pyrethrins (RID Mousse, RID Shampoo, R&C, A200)

Treatment of P humanus infestations. Stimulates nervous system of parasite, causing seizures and death. First-line treatment in head, pubic, and severe body louse infestation.

Adult

Apply shampoo to dry hair and allow to set for 10 min before rinsing; repeat in 1 wk prn

Pediatric

Apply as in adults

Pregnancy

X - Contraindicated; benefit does not outweigh risk

Precautions

Do not apply to eyes, face, or mucous membranes; discontinue use if irritation occurs


Ivermectin (Mectizan)

Binds selectively with glutamate-gated chloride ion channels in invertebrate nerve and muscle cells, causing cell death. Half-life is 16 h; metabolized in liver. DOC for onchocerciasis and strongyloidiasis. Recently shown to be effective against pediculosis but not yet approved by FDA. Not effective against nits.

Adult

12 mg PO as single dose; may repeat in 1 wk prn

Pediatric

<5 years: Not recommended
>5 years: 0.2 mg/kg PO as single dose

May interact with other ligand-gated chloride channels, such as those gated by GABA; should not be used with drugs that have similar effects (eg, benzodiazepines, barbiturates, valproic acid)

Documented hypersensitivity; meningitis

Pregnancy

C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus

Precautions

Adverse effects include nausea, vomiting, and, uncommonly, ophthalmologic reactions (eg, corneal opacity, uveitis, conjunctivitis, optic neuritis)


Lindane (Kwell, Scabene)

Stimulates nervous system of parasite, causing seizures and death. Chlorinated insecticide available as 1% lotion, cream, and shampoo. Second-line treatment if other agents fail or are not tolerated. Not very safe in children because of transcutaneous absorption that leads to neurotoxicity. Overall, permethrin is a safer choice.

Adult

Shampoo: Apply to dry head or pubic hair and surrounding areas; allow to set for 4 min, then lather for 4 min and rinse; repeat in 7 d prn
Lotion: Apply to affected skin/hair; put on clean clothing; rinse off in 8-12 h

Pediatric

Infants and children: Apply thin film topically over entire body, including hairline, neck, scalp, temple, and forehead; leave on 6-8 h before washing off with water; may repeat in 1 wk if necessary; not to exceed 30 g/application

Oil-based hairdressings may increase toxicity of lindane

Documented hypersensitivity; neonates; acutely swollen skin or Norwegian scabies

Pregnancy

B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals

Precautions

Caution if history of seizures; do not apply to eyes, face, or mucous membranes; caution in pregnancy; adverse reactions have been reported (eg, DIC, aplastic anemia)


Malathion (Ovide)

Recently approved (1999) by US FDA to treat head lice. Irreversible cholinesterase inhibitor that is hydrolyzed and therefore detoxified rapidly by mammals but not by insects; ovicidal and pediculicidal. Binds to hair and provides some residual protection after therapy. Available as 0.5% and 1% aqueous-based lotions.

Adult

Apply lotion to dry hair; leave on 8-12 h, rinse; repeat in 7 d prn

Pediatric

<2 years: Not recommended
>2 years: Apply as in adults

None reported; however, potential for interaction with aminoglycosides and antimyasthenics

Pregnancy

B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals

Precautions

Contains flammable alcohol; do not expose lotion or wet hair to open flame or electric heat (eg, hair dryers); allow hair to dry naturally and uncovered following application; avoid contact with eyes; flush eyes immediately with water if contact occurs


Mercuric oxide

Ointment (1%) is treatment of choice for Phthirus palpebrarum. For louse infestation of eyelashes, inspect eyelids and remove nits mechanically.

Adult

Apply to eyelashes qid for 14 d

Pediatric

Apply as in adults

Not to be used with topical sulfur or iodine compounds

Pregnancy

C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus

Precautions

Avoid direct contact with eyes; adverse effects include sensitization, contact dermatitis, and mercury poisoning (eg, nausea, headache, dizziness, gingivitis); discontinue use if persistent erythema, pain, or edema occurs


Isopropyl myristate (Resultz)

Not available in the United States (currently in phase III clinical trials). Available in Canada and Europe. Noninsecticide-based drug containing isopropyl myristate, an ingredient commonly used in cosmetics. Mode of action is a mechanical process that weakens the waxy shell of lice, resulting in internal fluid loss and dehydration.

Adult

Apply to dry hair and massage into hair until the scalp and back and sides of neck are thoroughly wet; leave on for 10 min, then rinse with warm water; repeat in 7 days to kill any eggs that might have hatched
Protect eyes with towel or washcloth during application

Pediatric

<4 years: Not established
>4 years: Administer as in adults

Pregnancy

C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus

Precautions

For external use only; do not use near eyes; if contact with eyes, immediately flush with water; soak all combs and brushes in hot water for 10 min; carefully inspect family members daily between treatments and for at least 2 wk after treatment; stop use if skin irritation or infection occurs, or infestation of eyebrows or eye lashes occurs


Benzyl alcohol lotion

Benzyl alcohol inhibits lice from closing their respiratory spiracles, allowing the lotion to obstruct the spiracles, which ultimately results in asphyxiation. Does not elicit ovicidal activity. Contains 5% benzyl alcohol.

Adult

Apply lotion to dry hair, using enough to completely saturate scalp and hair; rinse off with water after 10 min; repeat treatment in 1 wk

Pediatric

<6 months: Do not use
>6 months: Apply as in adults

Pregnancy

B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals

Precautions

May cause irritation to skin, scalp, and eyes (avoid eye exposure and flush immediately with water if contact occurs); application site anesthesia and hypoesthesia may occur; serious adverse events (eg, respiratory distress, seizure, coma) and death with benzyl alcohol have been well documented in premature infants; IV administration of products containing benzyl alcohol has been associated with neonatal gasping syndrome consisting of severe metabolic acidosis, gasping respirations, progressive hypotension, seizures, CNS depression, intraventricular hemorrhage, and death in preterm, low birth weight infants; neonates (ie, <1 mo or preterm infants with a corrected age <44 wk) could be at risk for gasping syndrome if treated

Anti-infectives

Therapy must be comprehensive and cover all likely pathogens in the context of this clinical setting.


Trimethoprim and sulfamethoxazole (Septra, Bactrim DS)

Normally used to treat Pneumocystis carinii infection, acne, and toxoplasmosis. Commonly used as prophylaxis against UTIs. Shown to be effective as a pediculicide.

Adult

7-10 mg/kg TMP PO for 7 d

Pediatric

<6 months: Not recommended
>6 months: Administer as in adults

May increase PT when used with warfarin (perform coagulation tests and adjust dose accordingly); coadministration with dapsone may increase blood levels of both drugs; coadministration of diuretics increases incidence of thrombocytopenia purpura in elderly people; phenytoin levels may increase with coadministration; may potentiate effects of methotrexate in bone marrow depression; hypoglycemic response to sulfonylureas may increase with coadministration; may increase levels of zidovudine

Documented hypersensitivity; megaloblastic anemia due to folate deficiency

Pregnancy

C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus

Precautions

Discontinue at first appearance of skin rash or any sign of adverse reaction; obtain CBC counts frequently; discontinue therapy if significant hematologic changes occur; goiter, diuresis, and hypoglycemia may occur with sulfonamides; prolonged IV infusions or high doses may cause bone marrow depression (if signs occur, give 5-15 mg/d leucovorin); caution in folate deficiency (eg, persons with chronic alcoholism, elderly people, those receiving anticonvulsant therapy, those with malabsorption syndrome); hemolysis may occur in individuals with G-6-PD deficiency; patients with AIDS may not tolerate or respond to TMP-SMZ; caution in renal or hepatic impairment (perform urinalyses and renal function tests during therapy); administer fluids to prevent crystalluria and stone formation


Fluorescein dye strips (SoftGlo strips)

Used with white petrolatum. This is an off-label use of dye strips used in the diagnosis of corneal abrasion.

Adult

Apply to eyelashes nightly for 3 nights

Pediatric

Apply as in adults

Pregnancy

C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus

Precautions

Vision may become blurred with use of white petrolatum

More on Pediculosis

Overview: Pediculosis
Differential Diagnoses & Workup: Pediculosis
Treatment & Medication: Pediculosis
Follow-up: Pediculosis
Multimedia: Pediculosis
References

References

  1. Araujo A, Ferreira LF, Guidon N, et al. Ten thousand years of head lice infection. Parasitol Today. Jul 2000;16(7):269. [Medline].

  2. Burkhart CN, Burkhart CG. Fomite transmission in head lice. J Am Acad Dermatol. Jun 2007;56(6):1044-7. [Medline].

  3. Mimouni D, Ankol OE, Gdalevich M, et al. Seasonality trends of Pediculosis capitis and Phthirus pubis in a young adult population: follow-up of 20 years. J Eur Acad Dermatol Venereol. May 2002;16(3):257-9. [Medline].

  4. Willems S, Lapeere H, Haedens N, et al. The importance of socio-economic status and individual characteristics on the prevalence of head lice in schoolchildren. Eur J Dermatol. Sep-Oct 2005;15(5):387-92. [Medline].

  5. Akisu C, Aksoy U, Delibas SB, Ozkoc S, Sahin S. The prevalence of head lice infestation in school children in izmir, Turkey. Pediatr Dermatol. Jul-Aug 2005;22(4):372-3. [Medline].

  6. Rupes V, Vlcková J, Mazánek L, Chmela J, Ledvinka J. [Pediatric head lice: taxonomy, incidence, resistance, delousing]. Epidemiol Mikrobiol Imunol. Aug 2006;55(3):112-9. [Medline].

  7. Di Stefani A, Hofmann-Wellenhof R, Zalaudek I. Dermoscopy for diagnosis and treatment monitoring of pediculosis capitis. J Am Acad Dermatol. May 2006;54(5):909-11. [Medline].

  8. Izri A, Chosidow O. Efficacy of machine laundering to eradicate head lice: recommendations to decontaminate washable clothes, linens, and fomites. Clin Infect Dis. Jan 15 2006;42(2):e9-10. [Medline].

  9. Foucault C, Ranque S, Badiaga S, et al. Oral ivermectin in the treatment of body lice. J Infect Dis. Feb 1 2006;193(3):474-6. [Medline].

  10. Nordt SP, Chew G. Acute lindane poisoning in three children. J Emerg Med. Jan 2000;18(1):51-3. [Medline].

  11. Mumcuoglu KY, Miller J, Zamir C, Zentner G, Helbin V, Ingber A. The in vivo pediculicidal efficacy of a natural remedy. Isr Med Assoc J. Oct 2002;4(10):790-3. [Medline].

  12. Benzyl alcohol lotion 5% [package insert]. Atlanta, GA: Sciele Pharma Inc; 2009. [Full Text].

  13. Akisu C, Delibas SB, Aksoy U. Albendazole: single or combination therapy with permethrin against pediculosis capitis. Pediatr Dermatol. Mar-Apr 2006;23(2):179-82. [Medline].

  14. Roberts RJ, Casey D, Morgan DA, Petrovic M. Comparison of wet combing with malathion for treatment of head lice in the UK: a pragmatic randomised controlled trial. Lancet. Aug 12 2000;356(9229):540-4. [Medline].

  15. Mumcuoglu KY, Gallili N, Reshef A, et al. Use of human lice in forensic entomology. J Med Entomol. Jul 2004;41(4):803-6. [Medline].

  16. Angel TA, Nigro J, Levy ML. Infestations in the pediatric patient. Pediatr Clin North Am. Aug 2000;47(4):921-35, viii. [Medline].

  17. Burkhart CN, Burkhart CG. Bacterial symbiotes, their presence in head lice, and potential treatment avenues. J Cutan Med Surg. Jan-Feb 2006;10(1):2-6. [Medline].

  18. Burkhart CN, Burkhart CG. Head lice: scientific assessment of the nit sheath with clinical ramifications and therapeutic options. J Am Acad Dermatol. Jul 2005;53(1):129-33. [Medline].

  19. Chosidow O. Scabies and pediculosis. Lancet. Mar 4 2000;355(9206):819-26. [Medline].

  20. Cunha BA. Antibiotic Essentials. Royal Oak, Mich: Physicians Press; 2005.

  21. Downs AM, Stafford KA, Coles GC. Head lice: prevalence in schoolchildren and insecticide resistance. Parasitol Today. Jan 1999;15(1):1-4. [Medline].

  22. Elston DM. Drug-resistant lice. Arch Dermatol. Aug 2003;139(8):1061-4. [Medline].

  23. Elston DM. Drugs used in the treatment of pediculosis. J Drugs Dermatol. Mar-Apr 2005;4(2):207-11. [Medline].

  24. Gillis D, Slepon R, Karsenty E, Green M. Seasonality and long-term trends of pediculosis capitis and pubis in a young adult population. Arch Dermatol. May 1990;126(5):638-41. [Medline].

  25. Jacobson CC, Abel EA. Parasitic infestations. J Am Acad Dermatol. Jun 2007;56(6):1026-43. [Medline].

  26. Katzung BG. Basic & Clinical Pharmacology. 7th ed. Stamford, Conn: Appleton & Lange; 1998.

  27. Klaus S, Shvil Y, Mumcuoglu KY. Generalized infestation of a 3 1/2-year-old girl with the pubic louse. Pediatr Dermatol. Mar 1994;11(1):26-8. [Medline].

  28. Ko CJ, Elston DM. Pediculosis. J Am Acad Dermatol. Jan 2004;50(1):1-12; quiz 13-4. [Medline].

  29. Lettau LA. Nosocomial transmission and infection control aspects of parasitic and ectoparasitic diseases. Part III. Ectoparasites/summary and conclusions. Infect Control Hosp Epidemiol. Mar 1991;12(3):179-85. [Medline].

  30. Markell EK, Voge M, John DT. Medical Parasitology. 7th ed. Philadelphia, Pa: WB Saunders; 1992.

  31. Mathias RG, Wallace JF. Man's closest companions. Can Fam Physician. 1987;33:124-6.

  32. Mougabure Cueto G, Gonzalez Audino P, Vassena CV, Picollo MI, Zerba EN. Toxic effect of aliphatic alcohols against susceptible and permethrin-resistant Pediculus humanus capitis (Anoplura: Pediculidae). J Med Entomol. May 2002;39(3):457-60. [Medline].

  33. Mumcuoglu KY, Klaus S, Kafka D, et al. Clinical observations related to head lice infestation. J Am Acad Dermatol. Aug 1991;25(2 Pt 1):248-51. [Medline].

  34. Schmidt GD, Roberts LS. Foundations of Parasitology. 4th ed. St. Louis, Mo: Times Mirror/Mosby; 1989.

  35. Silburt BS, Parsons WL. Scalp infestation by Phthirus pubis in a 6-week-old infant. Pediatr Dermatol. Sep 1990;7(3):205-7. [Medline].

  36. Takano-Lee M, Edman JD, Mullens BA, Clark JM. Transmission potential of the human head louse, Pediculus capitis (Anoplura: Pediculidae). Int J Dermatol. Oct 2005;44(10):811-6. [Medline].

  37. Parfitt K, ed. The Complete Drug Reference. 32nd ed. London, UK: Pharmaceutical Press; 1999.

  38. Wilson P. The science behind head lice treatment. Practitioner. Nov 1999;243(1604):824-6, 829. [Medline].

  39. Yoon KS, Gao JR, Lee SH, et al. Permethrin-resistant human head lice, Pediculus capitis, and their treatment. Arch Dermatol. Aug 2003;139(8):994-1000. [Medline].

Further Reading

Keywords

pediculosis, lice, crabs, louse infestation, lice infestation, ectoparasites, pubic lice, pubic louse, head lice, head louse, body lice, body louse, Pediculus humanus capitis, P humanus capitis, Pediculus humanus corporis, P humanus corporis, Phthirus pubis, P pubis, Pediculus humanus humanus, P humanus humanus, human pests, Anoplura, sucking lice, insect infestation, insect bite, nit, vector-borne disease, typhus, relapsing fever, trench fever, plica polonica, vagabond disease, vagabond skin, pediculicide, permethrin, lindane, malathion, mercuric oxide ointment, pyrethrin, piperonyl butoxide, hexachlorocyclohexane

Contributor Information and Disclosures

Author

Lyn Guenther, MD, FRCP(C), Professor, Department of Medicine, Division of Dermatology, University of Western Ontario; Chief of Dermatology, London Health Sciences Center; Medical Director, The Guenther Dermatology Research Centre, Canada
Lyn Guenther, MD, FRCP(C) is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American Society for Dermatologic Surgery, Canadian Dermatology Association, Canadian Medical Association, College of Physicians and Surgeons of Ontario, International Society for Dermatologic Surgery, Ontario Medical Association, Royal College of Physicians and Surgeons of Canada, Society for Investigative Dermatology, and Society for Pediatric Dermatology
Disclosure: L'Oreale Consulting fee Consulting

Coauthor(s)

Sheilagh Maguiness, BSc, MD, Department of Dermatology, University of Alberta
Disclosure: Nothing to disclose.

Thomas W Austin, MD, Professor Emeritus, Department of Medicine, Division of Infectious and Sexually Transmitted Diseases, University of Western Ontario, Canada
Thomas W Austin, MD is a member of the following medical societies: American Venereal Disease Association, Canadian Infectious Disease Society, College of Physicians and Surgeons of Ontario, Ontario Medical Association, and Royal College of Physicians and Surgeons of Canada
Disclosure: Nothing to disclose.

Medical Editor

Jeffrey M Zaks, MD, Clinical Associate Professor of Medicine, Wayne State University School of Medicine; Vice President, Medical Affairs, Chief Medical Officer, Department of Internal Medicine, Providence Hospital
Jeffrey M Zaks, MD is a member of the following medical societies: American College of Cardiology, American College of Healthcare Executives, American College of Physician Executives, and American Medical Association
Disclosure: Nothing to disclose.

Pharmacy Editor

Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine
Disclosure: Nothing to disclose.

Managing Editor

Joseph F John Jr, MD, FACP, FIDSA, FSHEA, Clinical Professor of Medicine, Molecular Genetics and Microbiology, Medical University of South Carolina; Associate Chief of Staff for Education, Ralph H Johnson Veterans Affairs Medical Center
Disclosure: BioMerieux Honoraria Review panel membership; Cubist Honoraria Review panel membership; Pfizer Honoraria Speaking and teaching; Merck Stock dividends stock holdings

CME Editor

Eleftherios Mylonakis, MD, Clinical and Research Fellow, Department of Internal Medicine, Division of Infectious Diseases, Massachusetts General Hospital
Eleftherios Mylonakis, MD is a member of the following medical societies: American Association for the Advancement of Science, American College of Physicians, American Society for Microbiology, and Infectious Diseases Society of America
Disclosure: Nothing to disclose.

Chief Editor

Burke A Cunha, MD, Professor of Medicine, State University of New York School of Medicine at Stony Brook; Chief, Infectious Disease Division, Winthrop-University Hospital
Burke A Cunha, MD is a member of the following medical societies: American College of Chest Physicians, American College of Physicians, and Infectious Diseases Society of America
Disclosure: Nothing to disclose.

RELATED MEDSCAPE ARTICLES
Articles
 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.